Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fragmin added to standard therapy in lung cancer
ISRCTN80812769Phase 3Completed
- Sponsor
- Velindre University NHS Trust
- Start
- Jan 2006
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of dalteparin in bronchial carcinoma (2 arms), sponsored by Velindre University NHS Trust. Primary endpoint: Overall survival. Started Jan 2006; status: completed.
02
Drugs
dalteparin
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ISRCTN80812769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN80812769.